Condition

Epithelial Ovarian Cancer clinical trials and research

• 37Clinical trials
• 17NIH research projects
• 1New in 30 days
• 41Countries

Newest Epithelial Ovarian Cancer clinical trials

All recruiting trials (37)

• VT-101 in Advanced Ovarian Cancer: early safety study in adults

  This early-phase trial tests VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer to see if it is safe, how the body handles it, and whether there are any initial signs of activity.

  Recruiting Phase 1 University of Iowa · Iowa City, Iowa · NCT07905677

• Torvutatug samrotecan plus bevacizumab as first-line maintenance in non-HRD advanced epithelial ovarian cancer

  This trial tests whether adding torvu-samrotecan to bevacizumab after standard chemotherapy helps people with non-HRD advanced epithelial ovarian cancer live longer without the cancer worsening compared with bevacizumab alone.

  Recruiting at 4 sites Phase 3 AstraZeneca · Tamarac, Florida and 219 other locations · NCT07851025

• Whole-body metabolic activity as a predictor of chemotherapy response in epithelial ovarian cancer

  This study tests whether whole-body metabolic activity can predict how well epithelial ovarian cancer responds to chemotherapy.

  Recruiting University of Tennessee Graduate School of Medicine · Knoxville, Tennessee · NCT07764133

• [68Ga]BED003 PET imaging to see fibroblast activity in selected cancers

  This study tests a PET imaging agent, [68Ga]BED003, to see how well it detects tumors in colorectal, gastric, pancreatic, ovarian, and invasive lobular breast cancers.

  Recruiting at 5 sites Phase 2 Blue Earth Diagnostics · Bergamo, Lombardy and 5 other locations · NCT07702292

• Dual-target CAR-NK Cells for Peritoneal Cancers of the Ovary, Fallopian Tube, or Pseudoperitoneal Disease

  This trial tests a dual-target CAR-NK cell therapy for people with recurrent or hard-to-treat epithelial ovarian, fallopian tube, or primary peritoneal cancer who express two or more specific tumor markers.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07617753

• Dual-Target CAR-NK Cells for Recurrent or Refractory Epithelial Ovarian Cancer

  This trial tests EB-DUALNK, a dual-target CAR-NK cell therapy, in adults with recurrent or refractory epithelial ovarian, fallopian tube, or peritoneal cancer to see if it can safely help the cancer shrink or stay controlled.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07589543

• Daphnetin plus TC chemotherapy and targeted maintenance after surgery for stage III–IV epithelial ovarian cancer

  This trial tests whether adding daphnetin capsules to standard paclitaxel‑carboplatin chemotherapy and then combining daphnetin with targeted maintenance can help people with stage III–IV epithelial ovarian cancer who had R0 or R1 surgery.

  Recruiting The First Hospital of Jilin University · Changchun, Jilin · NCT07495397

• Dual-target CAR-NK therapy for recurrent ovarian, fallopian tube, or primary peritoneal cancer

  This trial tests whether dual-target CAR‑NK cells can shrink tumors in people with recurrent or refractory epithelial ovarian, fallopian tube, or primary peritoneal cancer whose tumors express at least two of MSLN, FRα, or MUC16.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07480954

• PET scan using [18F]FPyQCP to image fibroblast activation protein in several cancers

  This test tries a new PET imaging tracer, [18F]FPyQCP, to see if it helps detect colorectal, gastric, pancreatic ductal adenocarcinoma, invasive lobular breast, and epithelial ovarian cancers in adults.

  Recruiting Phase 1/2 Blue Earth Diagnostics · New York, New York and 1 other locations · NCT07432633

• Isoquercetin for people with ovarian cancer

  This trial will test whether taking isoquercetin along with first-line chemotherapy can lower blood markers tied to blood clot risk in people with ovarian cancer.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Boston, Massachusetts and 7 other locations · NCT07303894

• AZD5335 versus mirvetuximab or chemotherapy for FRα-high and FRα-low platinum-resistant ovarian, fallopian tube, or peritoneal cancer

  This will test whether AZD5335 works better than mirvetuximab for FRα-high tumors or better than single-agent chemotherapy for FRα-low tumors in women with high-grade, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 95 sites Phase 3 AstraZeneca · Birmingham, Alabama and 298 other locations · NCT07218809

• Centralization of Epithelial Ovarian Cancer Care and Outcomes in Italy

  This study tests how concentrating ovarian cancer treatment in high-volume centers during 2018–2023 affected patient outcomes.

  Recruiting at 5 sites Azienda USL Reggio Emilia - IRCCS · Carpi, Modena and 6 other locations · NCT07075939

• BL-B01D1 versus doctor‑chosen chemotherapy for platinum‑resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer

  This tests whether BL-B01D1 works better than the doctor’s choice of chemotherapy for adults with platinum‑resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06994195

• IMNN-001 combined with standard chemotherapy for newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer

  This trial tests whether adding IMNN-001 (an intraperitoneal IL-12 plasmid therapy) to standard paclitaxel/carboplatin chemotherapy helps people with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 10 sites Phase 3 Imunon · Orlando, Florida and 9 other locations · NCT06915025

• Combining carboplatin with mirvetuximab soravtansine before surgery for FRα-positive advanced serous ovarian, fallopian tube, or primary peritoneal cancer

  This will test whether giving mirvetuximab soravtansine with carboplatin before surgery helps people with newly diagnosed FRα-positive advanced-stage serous ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 71 sites Phase 2 AbbVie · Birmingham, Alabama and 72 other locations · NCT06890338

• Evaluating TORL-1-23 for advanced platinum-resistant ovarian cancer

  This study is testing a new treatment called TORL-1-23 for women with advanced ovarian cancer that doesn't respond to standard platinum-based therapies to see if it can help them.

  Recruiting at 66 sites Phase 2 TORL Biotherapeutics, LLC · Phoenix, Arizona and 65 other locations · NCT06690775

• Immune cell therapy for recurrent ovarian cancer

  This study is testing a new immune cell therapy called 27T51 to see if it can help women with recurrent ovarian cancer feel better and fight their disease.

  Recruiting at 5 sites Phase 1 Regeneron Pharmaceuticals · Boston, Massachusetts and 4 other locations · NCT06469281

• Testing a new drug ETX-19477 for advanced solid tumors

  This study is testing a new drug called ETX-19477 to see if it can help people with advanced solid tumors that haven't responded to other treatments.

  Recruiting at 14 sites Phase 1/2 858 Therapeutics, Inc. · Phoenix, Arizona and 13 other locations · NCT06395519

• Fasting during chemotherapy for ovarian cancer

  This study is testing if intermittent fasting during chemotherapy can help improve quality of life and treatment results for people with ovarian cancer compared to regular eating habits.

  Recruiting Case Comprehensive Cancer Center · Cleveland, Ohio · NCT06386887

• Validation of the Cukurova Score for ovarian cancer treatment decisions

  This study is testing a new scoring system to help doctors decide the best treatment options for patients with advanced ovarian cancer.

  Recruiting Cukurova University · Adana · NCT06378905

• Using personalized vaccines to prevent recurrence in ovarian cancer patients after surgery

  This study is testing whether personalized vaccines can help prevent ovarian cancer from coming back after surgery by monitoring specific markers in the blood.

  Recruiting Phase 2/3 Second Affiliated Hospital of Wenzhou Medical University · Wenzhou, Zhejiang · NCT06341907

• Using modified T cells to treat recurrent ovarian cancer

  This study is testing a new treatment using modified immune cells to see if it can help people with recurrent ovarian cancer that hasn't responded to standard treatments.

  Recruiting Phase 1 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06305299

• Characterizing the immune landscape in newly diagnosed epithelial ovarian cancer

  This study is looking to understand the immune system's response in women newly diagnosed with different types of ovarian cancer by collecting samples from those starting surgery or chemotherapy, and comparing them to women having surgery for non-cancer issues.

  Recruiting Oncology Institute of Southern Switzerland · Bellinzona · NCT05984875

• Treatment of advanced solid tumors with AVZO-021

  This study is testing a new oral medication called AVZO-021 to see if it can safely help people with advanced solid tumors, especially certain types of breast cancer and other cancers with specific genetic changes.

  Recruiting at 13 sites Phase 1/2 Avenzo Therapeutics, Inc. · New Haven, Connecticut and 12 other locations · NCT05867251

• Evaluating the role of advanced imaging in gynecological cancers

  This study is testing if advanced imaging techniques can help doctors better diagnose and treat women with cervical, endometrial, and ovarian cancers.

  Recruiting Region Västerbotten · Umeå · NCT05855941

• Dendritic cell vaccination for ovarian cancer treatment

  This study is testing a special vaccine made from immune cells to see if it can help women with advanced ovarian cancer feel better while they receive chemotherapy.

  Recruiting Phase 1/2 Radboud University Medical Center · Nijmegen, Gelderland · NCT05773859

• Comparing stress reduction methods to standard care for ovarian cancer patients

  This study is testing if a mix of medications and therapies can help reduce stress in women with advanced ovarian cancer before their surgery, compared to those getting standard care.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT05429970

• Tinzaparin treatment for women with advanced ovarian cancer receiving chemotherapy

  This study is testing whether the blood thinner tinzaparin can help women with advanced ovarian cancer feel better while they are getting chemotherapy.

  Recruiting at 7 sites Phase 2 University Hospital, Linkoeping · Eksjö, Eksjö and 7 other locations · NCT05284552

• Hepato-celiac lymphadenectomy for survival in primary or relapsed ovarian-related cancers

  This trial will try hepato-celiac lymphadenectomy to see if removing hepato-celiac lymph nodes helps adults with advanced or platinum-sensitive relapsed epithelial ovarian, fallopian tube, or primary peritoneal cancer that has spread to those nodes.

  Recruiting Shanghai Gynecologic Oncology Group · Shanghai · NCT05236686

• Imaging solid tumors using a new tracer called 68Ga-FAPI

  This study is testing a new imaging method using a special tracer to see if it can help doctors better detect certain types of cancer in patients who are having surgery.

  Recruiting Phase 1 Karolinska University Hospital · Stockholm · NCT05172310

• Comparing two surgical methods for ovarian cancer treatment

  This study tests which surgical method, either removing part of the rectum or just shaving the tumor, works better for people with advanced ovarian cancer that has spread to that area.

  Recruiting Cukurova University · Adana and 1 other locations · NCT04665635

• Combination treatment of Olaparib and Durvalumab for advanced ovarian cancer

  This study is testing if a combination of two drugs, Olaparib and Durvalumab, can help people with advanced ovarian cancer feel better after their initial chemotherapy.

  Recruiting at 6 sites Phase 2 AGO Research GmbH · Mannheim, Baden-Wurttemberg and 5 other locations · NCT04644289

• Evaluating ZN-c3 for patients with ovarian cancer

  This study is testing a new treatment called ZN-c3 combined with other chemotherapy drugs to see if it is safe and effective for people with advanced ovarian cancer.

  Recruiting at 12 sites Phase 1 K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Aurora, Colorado and 34 other locations · NCT04516447

• Investigating BCA101 for advanced solid tumors driven by EGFR

  This study is testing a new treatment called BCA101 to see if it can help people with advanced solid tumors that are driven by EGFR, especially those who haven't responded to other therapies.

  Recruiting at 21 sites Phase 1 Bicara Therapeutics · La Jolla, California and 20 other locations · NCT04429542

• Comparing chemotherapy and observation for early-stage ovarian cancer after surgery

  This study is testing whether giving chemotherapy after surgery helps women with early-stage ovarian cancer live longer compared to just monitoring their condition.

  Recruiting at 103 sites Phase 3 Japanese Gynecologic Oncology Group · Nagakute-shi, Aichi-ken and 102 other locations · NCT04063527

• Identifying factors in platinum resistance for ovarian cancer

  This study is trying to find out why some people with ovarian cancer don’t respond to standard platinum chemotherapy, by collecting information and samples from patients receiving this treatment.

  Recruiting Institut Claudius Regaud · Toulouse · NCT03954171

• Identifying immune markers in ovarian cancer patients

  This study is trying to find immune markers in women with ovarian cancer to see how they relate to treatment outcomes.

  Recruiting Leiden University Medical Center · Leiden · NCT03862677

NIH-funded research (17)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• TAG72 CAR-T therapy for recurrent epithelial ovarian cancer

  A targeted CAR-T cell therapy delivered into the abdomen for women with recurrent epithelial ovarian cancer to attack cancer cells expressing TAG72.

  NIH research Beckman Research Institute/city of Hope · Duarte, United States · NIH-11384880

• Liquid biopsy clues: plasma bacteria as early warning for epithelial ovarian cancer

  A patient-friendly look at a new approach that uses tiny bacteria signals in blood to help detect ovarian cancer early.

  NIH research University of Kansas Medical Center · Kansas City, United States · NIH-11382454

• Understanding how cancer cells talk to the immune system and how to use that to treat ovarian cancer

  This grant studies how aging-like changes in ovarian cancer cells drive harmful signals and tests new ways to block those signals to improve treatment.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11370676

• Targeting the immune system to help treat recurrent ovarian cancer

  Aims to test a new approach that blocks a part of the immune system (complement) to boost anticancer immunity in people with recurrent ovarian cancer and fluid buildup.

  NIH research Roswell Park Cancer Institute Corp · Buffalo, United States · NIH-11364172

• Th17-inducing vaccine plus pembrolizumab for recurrent ovarian cancer

  A phase I/II study tests a vaccine that activates Th17 immune cells together with pembrolizumab to help fight recurrent ovarian cancer.

  NIH research Mayo Clinic Jacksonville · Jacksonville, United States · NIH-11361561

• CAR T-cell therapy targeting TAG72 for recurrent epithelial ovarian cancer

  This trial tries a CAR T‑cell treatment that targets the TAG72 protein for people with recurrent epithelial ovarian cancer, given directly into the abdomen.

  NIH research Beckman Research Institute/city of Hope · Duarte, United States · NIH-11336746

• How fat use changes make ovarian cancer more invasive and chemo‑resistant

  This project looks at whether shifts in how ovarian cancer cells use fats make them more likely to spread and resist chemotherapy for people with epithelial ovarian cancer.

  NIH research Brown University · Providence, United States · NIH-11146614

• Boosting the body's defenses against recurrent ovarian cancer and managing fluid buildup

  This project explores a new way to strengthen the immune system against recurrent ovarian cancer and reduce fluid accumulation by targeting a specific part of the immune response.

  NIH research Roswell Park Cancer Institute Corp · Buffalo, United States · NIH-11141676

• Understanding how ovarian cancer cells resist treatment and finding new ways to overcome it

  This work explores how ovarian cancer cells become resistant to chemotherapy and aims to find new treatment combinations that can stop this resistance.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11136975

• Combining a special vaccine with immunotherapy for recurrent ovarian cancer

  This research combines a unique vaccine with an immunotherapy drug to help patients with ovarian cancer that has returned.

  NIH research Mayo Clinic Jacksonville · Jacksonville, United States · NIH-11114072

• Investigating a specific protein's role in ovarian cancer progression

  This study is looking at a protein called Doppel that appears in ovarian cancer to see if it can help us find the cancer earlier and create better treatments, which could be really helpful for patients dealing with this condition.

  NIH research University of Utah · Salt Lake City, United States · NIH-11044391

• Using CAR T cells to target a specific cancer marker in ovarian cancer patients

  This study is testing a new treatment for women with recurrent ovarian cancer that uses special immune cells to help the body fight the cancer more effectively, especially by delivering these cells directly where the cancer is likely to spread.

  NIH research Beckman Research Institute/city of Hope · Duarte, United States · NIH-10914190

• Understanding how certain cells in ovarian cancer can promote tumor growth after treatment

  This study is looking at how certain cells in ovarian cancer can survive treatment and cause the cancer to come back, with the hope of finding new ways to target these tricky cells while keeping their helpful qualities, which could lead to better treatments for patients with ovarian cancer.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-10897891

• Understanding how lipid metabolism affects invasive ovarian cancer cells

  This study is looking at how some ovarian cancer cells become tough and hard to treat with chemotherapy, and it aims to find out what makes these cells survive and grow, which could help develop better treatments for patients with this type of cancer.

  NIH research Brown University · Providence, United States · NIH-10893352

• Enhancing the immune response against recurrent ovarian cancer

  This study is looking at how to boost the immune system's fight against recurrent ovarian cancer by using a special treatment called APL-2, and it's for patients who are dealing with this type of cancer and its related complications.

  NIH research Roswell Park Cancer Institute Corp · Buffalo, United States · NIH-10892999

• Combining a new vaccine with pembrolizumab for treating recurrent ovarian cancer

  This study is testing a new way to help women with recurrent ovarian cancer by using a vaccine to boost their immune system, followed by a medication called pembrolizumab to keep that immune response strong, with the hope of improving their treatment results.

  NIH research Mayo Clinic Jacksonville · Jacksonville, United States · NIH-10876253

• How calorie restriction affects immune cells to fight ovarian cancer

  This study is looking at how eating fewer calories might help your immune system fight epithelial ovarian cancer better by changing the way certain immune cells work, and it's aimed at finding new dietary tips that could make cancer treatments more effective for patients like you.

  NIH research Henry Ford Health System · Detroit, United States · NIH-10839842

Related topics

Quick answers

How many Epithelial Ovarian Cancer clinical trials are recruiting right now?

37, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 41 countries. The most sites are in United States (17 trials), China (9 trials), Australia (6 trials), France (5 trials), South Korea (5 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 7, Phase 1: 6, Phase 2: 6, Phase 3: 5. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →